The Role of Angiotensin Type I Receptor in the Regulation of Human Coronary Vascular Function
Status:
Completed
Trial end date:
2000-09-01
Target enrollment:
Participant gender:
Summary
The renin angiotensin system (RAS) plays an important physiological and pathophysiological
role in the control of blood pressure and plasma volume. Inhibition of the RAS is useful in
the treatment of hypertension, cardiac failure and in some patients with myocardial
infarction. Several recent clinical trials with angiotensin converting enzyme inhibitors
(ACEI) have shown that they also reduce the incidence of myocardial infarction, but the
mechanisms underlying this anti-ischemic effect are poorly understood. ACEI reduce
angiotensin II synthesis and prevent bradykinin degradation. Results from ongoing studies in
the Cardiology Branch (Protocol 95-H-0099) designed to investigate the link between ACEI and
the vascular endothelium indicate that ACEI improve both endothelial dysfunction and
metabolic coronary vasodilation, an effect that is partially mediated by bradykinin. The
current protocol is designed to investigate whether the beneficial effects of ACEI on
endothelial function are also partly due to inhibition of angiotensin II. The recent
development of selective angiotensin II type 1 (AT1) receptor antagonists allows us to
specifically examine the effects of angiotensin II on vasomotor activity.
Phase:
Phase 3
Details
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Treatments:
Angiotensin II Angiotensin II Type 1 Receptor Blockers Angiotensin Receptor Antagonists Angiotensinogen Giapreza